Drug intelligence / Profile preview

MOS102

Development stage: Preclinical
Lead developer: Mosaic Therapeutics
Modality: Small Molecules

Overview

MOS102 is a small molecule MDM2 inhibitor being developed by Mosaic Therapeutics for the treatment of p53 wild-type (WT) myelofibrosis. By inhibiting the E3 ubiquitin-protein ligase MDM2, MOS102 prevents the degradation of the p53 tumor suppressor protein, thereby restoring p53-mediated cell cycle arrest and apoptosis in malignant cells. The drug is currently in IND-enabling development, with a Phase 1b clinical trial planned for the first half of 2027. It is designed for use as a combination therapy to enhance therapeutic efficacy in myelofibrosis patients who retain wild-type p53 function.

Targets

MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on MOS102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOS102.

Explore the full profile